I Chair and Department of Gynecological Oncology and Gynecology is a specialist research center providing help in diagnostics and treatment of gynecological malignancies. The research work is focused on the processes of angiogenesis and lymphangiogenesis. Development of blood and lymphatic vessels is subject to research in a wide range of malignancies, including ovarian cancer, endometrial cancer and uterine sarcomas. Angiogenesis in malignancies of the female genital tract is investigated by using some modern 3D sonography that uses high-definition blood flow imaging. Ovarian Tumors and Early Ovarian Cancer Detection unit was established in 2002 and since that time more than 3500 patients with difficult to diagnose tumors have been consulted and treated in the Department. Ovarian cancer immunology studies are the second leading research fiekld in the 1st Chair Department of Gynecological Oncology and Gynecology. The Department is well equipped with diagnostic devices as well as a scientific laboratory. This allows for studies in the fields of imaging of masses, their immunology, biochemistry and molecular biology. Understanding immunological response in patients with ovarian cancer is the key to develop new, effective therapies, including immunological vaccines. In this area we are cooperating with prominent international research centers: Department of Surgery, University of Michigan and Department of Microbiology and Immunology, University of Arkansas. Results of our research are published in both Polish and international journals specializing in fields of gynecology, oncology, immunology and basic science.
If the inline PDF is not rendering correctly, you can download the PDF file here.
1. Czekierdowski A. Studies on angiogenesis in the benign and malignant ovarian neoplasms with the use of color and pulsed Doppler sonography and serum CA-125 CA-19.9 CA-72.4 and vascular endothelial growth factor measurements. Ann Univ Mariae Curie Sklodowska Med. 2002;57:113-31.
2. Czekierdowski A Smoleń A Bednarek W Kotarski J. Three dimensional sonography and 3D power angiography in differentiation of adnexal tumors. Ginekol Pol. 2002;73:1061-70.
3. Czekierdowski A Szymański M Szumiło J Kotarski J. Color Doppler blood flow measurements and microvessel density assessment in ovarian tumors. Ginekol Pol. 2003;74:695-700.
4. Timmerman D Testa AC Bourne T et al. International Ovarian Tumor Analysis Group. Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the International Ovarian Tumor Analysis Group. J Clin Oncol. 2005;23:8794-801.
5. Czekierdowski A Czekierdowska S Danilos J et al. Microvessel density and CpG island methylation of the THBS2 gene in malignant ovarian tumors. J Physiol Pharmacol. 2008;59 (Suppl 4):53-65.
6. Valentin L Ameye L Savelli L et al. Adnexal masses difficult to classify as benign or malignant using subjective assessment of gray-scale and Doppler ultrasound findings: logistic regression models do not help. Ultrasound Obstet Gynecol. 2011;38:456-65.
7. Daemen A Valentin L Fruscio R et al. Improving the preoperative classification of adnexal masses as benign or malignant by second-stage tests. Ultrasound Obstet Gynecol. 2011;37:100-6.
8. Timmerman D Van Calster B Testa AC et al. Ovarian cancer prediction in adnexal masses using ultrasound-based logistic regression models: a temporal and external validation study by the IOTA group. Ultrasound Obstet Gynecol. 2010;36:226-34
9. Testa A Kaijser J Wynants L Fischerova et al. Strategies to diagnose ovarian cancer: new evidence from phase 3 of the multicentre international IOTA study. Br J Cancer. 2014;111:680-8.
10. Van Calster B Van Hoorde K Valentin L et al. Diagnosing ovarian cancer using the ADNEX risk model: A diagnostic study to differentiate between benign borderline stage I invasive advanced stage invasive and secondary metastatic tumours. Br Med J. 2014;349:g5920.
11. Dharmalingam P Roopesh Kumar VR Verma SK. Vascular endothelial growth factor expression and angiogenesis in various grades and subtypes of meningioma. Indian J Pathol Microbiol. 2013;56:349-54.
12. Otrock ZA Makarem JA Shamseddine AI. Vascular endothelial growth factor family of ligands and receptors: Review. Blood Cells Mol Dis. 2007;38:258-268.
13. Wang Y Yao X Ge J et al. Can vascular endothelial growth factor and microvessels density be used as prognostic biomarkers for colorectal cancer? A systematic review and meta-analysis. Scientific World J. 2014;2014:102736.
14. Matsui Y Amano H Ito Y et al The role of vascular endothelial growth factor receptor-1 signaling in compensatory contralateral lung growth following unilateral pneumonectomy. Lab Invest; 2015.
15. Lu W Li P Shan Y et al. Discovery of biphenyl-based VEGFR-2 inhibitors. Part 3: Design synthesis and 3D-QSAR studies.Bioorg Med Chem. 2015;23(5):1044-54.
16. Wild J Staton C Chapple K Corfe B. Neuropilins: expression and roles in the epithelium. Int J Exp Pathol.2012;93(2):81-103.
17. Kärpänen T Heckman CA Kesktitalo S et. al. Functional interaction of VEGF-C and VEGF-D with neuropilin receptors. FASEB J. 2006;20:1462-72.
19. Li S Li Q. Cancer stem cells lymphangiogenesis and lymphatic metastasis. Cancer Letters. 2015;357:438-47.
20. Ji RC. Lymphatic endothelial cells tumor lymphangiogenesis and metastasis: New insights into intratumoral and peritumoral lymphatics. Cancer Metastasis Rev. 2006;25(4):677-94.
21. He Y Rajantie I Pajusola K et al. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res. 2005;65(11):4739-46.
22. Wigle JT Oliver G. Prox1 function is required for the development of the murine lymphatic system. Cell. 1999;98(6):769-78.
23. Van der Auwera I Cao Y Tille JC. First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. BJC. 2006;95:1611-25.
24. Potente M Gerhardt H Carmeliet P. Basic and therapeutic aspects of angiogenesis.Cell. 2011;146:873-87.
25. Gu B Alexander JS Gu Y et al. Expression of lymphatic vascular endothelial hyaluronan receptor-1 (LYVE-1) in the human placenta. Lymphatic Res Biol. 2007;4(1):11-7.
26. Omachi T Kawai Y Mizuno R et al. Immunohistochemical demonstration of proliferating lymphatic vessels in colorectal carcinoma and its clinicopathological significance. Cancer Lett. 2007;246(1-2):167-72.
27. Kędzia H. Pierwotne nabłonkowe nowotwort jajnika. In: H. Kędzia. Nowotwory narządów płciowych kobiety. Poznań: Ośrodek Wydawnictw Naukowych; 1997. p. 43-81.
28. Neijt J Engelholm S Tuxen M et. al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol. 2000;18:3084-92.
29. Ozols R Rubin S Thomas G et. al. Epithelial ovarian cancer. In: W. Hoskins C. Perez R. Young. Principles and Practice of Gynecologic Oncology. Philadelphia USA: Lippincott Williams and Wilkins; 2000. p. 981-1057.
30. Reinartz S Köhler S Schlebusch H et. al. Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clin Cancer Res. 2004;10:1580-87.
31. Helen T Hoskins P Miller D et. al. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. Int J Gynecol Cancer. 2005;15:1023-34.
32. Agus D Gordon M Taylor C et. al.. Phase I clinical study of pertuzumab a novel HER dimerization inhibitor in patients with advanced cancer. J Clin Oncol. 2005;23:2534-43.
33. Nicholson S Bomphray C Thomas H et. al. A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunol Immunother. 2004;53:809-16.
34. Berek J Hacker N Lichtenstein A et. al. Intraperitoneal recombinant alpha 2-interferon for ‘salvage’ immunotherapy in persistent epithelial ovarian cancer. Cancer Treat Rev. 1985;12 (Suppl. B):23-32.
35. Odunsi K Qian F Matsuzaki J et. al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci USA. 2007;104:12837-42.
36. Liu B Nash J Runowicz C et. al. Ovarian cancer immunotherapy: opportunities progresses and challenges. J Hematol Oncol. 2010;3:7.
37. Disis M Gooley T Rinn K et. al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptidebased vaccines. J Clin Oncol. 2002;20:2624-32.
38. Vlad A Kettel J Alajez N et. al. MUC1 immunobiology: from discovery to clinical applications. Adv Immunol. 2004;82:249-93.
39. Campbell I Freemont P Foulkes W et. al. An ovarian tumor marker with homology to vaccinia virus contains an IgV-like region and multiple transmembrane domains. Cancer Res. 1992;52:5416-20.
40. Kenemans P. CA 125 and OA 3 as target antigens for immunodiagnosis and immunotherapy in ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 1990;36:221-8.
41. Coliva A Zacchetti A Luison E et. al. 90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas. Cancer Immunol Immunother. 2005;54:1200-13.
42. Rosenblum M Shawver L Marks J et. al. Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity pharmacokinetics and in vivo efficacy studies in xenograft models. Clin Cancer Res. 1999;5:865-74.
43. Chang K Pastan I. Molecular cloning of mesothelin a differentiation antigen present on mesothelium mesotheliomas and ovarian cancers. Proc Natl Acad Sci USA. 1996;93:136-40.
44. Odunsi K Jungbluth A Stockert E et. al. NY-ESO-1 and LAGE-1 cancer- testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res. 2003;63:6076-83.
45. Sandmaier B Oparin D Holmberg L et. al. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy stem cell rescue and immunization with TheratopeSTn-KLH cancer vaccine. J Immunother. 1999;22:54-66.
46. Dallal R Lotze M. The dendritic cell and human cancer vaccines. Curr Opin Immunol. 2000;12:583-8.
47. Fong L Engleman E. Dendritic cells in cancer immunotherapy. Annu Rev Immunol. 2000;18:245-73.
48. Avigan D. Dendritic cells: development function and potential use for cancer immunotherapy. Blood Rev. 1999;13:51-64.
49. Tarte K Klein B. Dendritic cell-based vaccine: a promising approach for cancer immunotherapy. Leukemia. 1999;13:653-63.
50. Chiriva-Internati M Mirandola L Kast W et. al. Understanding the cross-talk between ovarian tumors and immune cells: mechanisms for effective immunotherapies. Int Rev Immunol. 2011;30:71-86.
51. Gong J Nikrui N Chen D et. al. Fusions of human ovarian carcinoma cells with autologus or allogeneic dendritic cells induce antitumor immunity. J Immunol. 2000;165:1705-11.
52. Kandalaft L Singh N Liao J et. al. The emergence of immunomodulation: Combinatorial immunochemotherapy opportunities for the next decade. Gynecol Oncol. 2010;116:222-33.